<p>以色列拉馬特甘，2025 年 12 月 24 日（全球新聞稿）——XTL 生物製藥有限公司（Nasdaq:XTLB）（TASE:XTLB.TA）（以下簡稱 “公司” 或 “XTL”）今天宣佈，已收到納斯達克證券市場有限責任公司（“納斯達克”）上市資格部門於 2025 年 12 月 22 日發出的通知函，通知公司根據 XTL 在過去 30 個連續交易日的收盤報價，目前未能滿足納斯達克持續上市要求，即每股最低報價為 1 美元的要求。</p>
<p>納斯達克的通知函並不會導致公司美國存托股票（“ADSs”）的立即退市，ADSs 將繼續在 “XTLB” 符號下不間斷交易。</p>
<p>根據納斯達克上市規則 5810(c)(3)(A)，公司有 180 個日曆天的合規期，直到 2026 年 6 月 22 日，以恢復合規。如果在這 180 天期間內，公司證券的收盤報價至少為 1 美元，且持續十個交易日，納斯達克將向 XTL 提供書面合規確認，此事將結束。</p>
<p>如果公司未能恢復合規，XTL 可能有資格獲得額外的時間。為符合資格，公司需要滿足公開持股的市場價值和納斯達克資本市場的所有其他初始上市標準，除了報價要求，並需要在第二個合規期內提供書面通知，表明其打算通過必要時進行反向股票拆分來彌補缺陷。如果 XTL 滿足這些要求，納斯達克將通知公司已獲得額外的 180 個日曆天。然而，如果納斯達克認為公司無法彌補缺陷，或公司其他方面不符合資格，納斯達克將發出通知，表明其證券將面臨退市。</p>
<p>XTL 目前正在評估恢復合規的選項，並打算及時恢復符合納斯達克的持續上市要求。儘管 XTL 將盡一切合理努力以達到規則 5550(a)(2) 的合規要求，但不能保證公司能夠恢復對該規則的合規，或在其他納斯達克持續上市要求方面保持合規。</p>
<p><strong>關於 XTL 生物製藥有限公司</strong></p>
<p>XTL 是一家知識產權組合公司。XTL 持有 The Social Proxy Ltd.（“Social Proxy”）100% 的股本，該公司是一家網絡數據公司，並已就 hCDR1 的知識產權組合進行再許可，以治療狼瘡疾病。Social Proxy 是一家網絡數據人工智能公司，開發並提供一個獨特的倫理、基於知識產權的代理數據提取平台，用於大規模的人工智能和商業智能應用。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本通訊包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的定義的前瞻性聲明。本通訊中包含的任何非歷史事實的陳述可能被視為前瞻性聲明。諸如 “繼續”、“將”、“可能”、“應該”、“期望”、“預計”、“計劃”、“打算”、“預期”、“相信”、“估計”、“預測”、“潛在” 等類似詞彙旨在識別此類前瞻性聲明。所有前瞻性聲明都涉及重大風險和不確定性，可能導致實際結果與前瞻性聲明中表達或暗示的結果有實質性差異，其中許多通常超出公司的控制範圍，且難以預測。這些風險和不確定性的例子包括但不限於（i）公司是否能夠收到與其 Hcdr1 知識產權相關的再許可費用，（ii）公司成功管理和整合 Social Proxy 及任何其他合資企業、業務收購、解決方案或技術的能力；（iii）意外的運營成本、交易成本及實際或或有負債；（iv）吸引和留住合格員工及關鍵人員的能力；（v）競爭加劇對公司未來業務的不利影響；（vi）公司保護其知識產權的能力；以及（vii）地方、行業及一般商業和經濟條件。可能導致實際結果與前瞻性聲明中表達或暗示的結果有實質性差異的其他因素可以在公司向證券交易委員會提交的最新 20-F 表格年度報告和 6-K 表格當前報告中找到。公司預計後續事件和發展可能導致其計劃、意圖和預期發生變化。公司不承擔任何義務，並明確聲明不打算或不承擔更新任何前瞻性聲明的責任，無論是由於新信息、未來事件還是其他原因，除非法律明確要求。前瞻性聲明僅在作出之日有效，不應被視為公司在任何後續日期的計劃和預期的代表。</p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p>投資者關係，XTL 生物製藥有限公司。</p>
<p>電話：+972 3 611 6666</p>
<p>電子郵件：info@xtlbio.com</p>
<p>www.xtlbio.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXhOeU0zTXpNMU9UWTJJelV3TURBMk5qUTNPQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXhOeU0zTXpNMU9UWTJJelV3TURBMk5qUTNPQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png"/></p>

XTL生物制藥

<p>XTL 生物製藥有限公司收到了納斯達克的通知，因未滿足每股最低出價要求 1 美元。該公司有 180 天的時間來恢復合規，可能通過反向股票拆分來實現。XTL 的股票將繼續以 “XTLB” 進行交易。如果未能實現合規，若滿足其他上市標準，XTL 可能會獲得額外的時間。該公司正在探索解決這一缺陷的選項</p>

<p>RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ <strong>Company</strong>” or “ <strong>XTL</strong>”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“ <strong>Nasdaq</strong>”), dated December 22, 2025, notifying the Company that based on XTL’s closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.</p>
<div class="lb-trans"><p>以色列拉馬特甘，2025 年 12 月 24 日（全球新聞稿）——XTL 生物製藥有限公司（Nasdaq:XTLB）（TASE:XTLB.TA）（以下簡稱 “公司” 或 “XTL”）今天宣佈，已收到納斯達克證券市場有限責任公司（“納斯達克”）上市資格部門於 2025 年 12 月 22 日發出的通知函，通知公司根據 XTL 在過去 30 個連續交易日的收盤報價，目前未能滿足納斯達克持續上市要求，即每股最低報價為 1 美元的要求。</p>
</div><p>The Nasdaq notification letter does not result in the immediate delisting of the Company’s American Depositary Shares (“ <strong>ADSs</strong>”), and the ADSs will continue to trade uninterrupted under the symbol “XTLB”.</p>
<div class="lb-trans"><p>納斯達克的通知函並不會導致公司美國存托股票（“ADSs”）的立即退市，ADSs 將繼續在 “XTLB” 符號下不間斷交易。</p>
</div><p>Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 22, 2026, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide XTL with written confirmation of compliance and this matter will be closed.</p>
<div class="lb-trans"><p>根據納斯達克上市規則 5810(c)(3)(A)，公司有 180 個日曆天的合規期，直到 2026 年 6 月 22 日，以恢復合規。如果在這 180 天期間內，公司證券的收盤報價至少為 1 美元，且持續十個交易日，納斯達克將向 XTL 提供書面合規確認，此事將結束。</p>
</div><p>In the event the Company does not regain compliance, XTL may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If XTL meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.</p>
<div class="lb-trans"><p>如果公司未能恢復合規，XTL 可能有資格獲得額外的時間。為符合資格，公司需要滿足公開持股的市場價值和納斯達克資本市場的所有其他初始上市標準，除了報價要求，並需要在第二個合規期內提供書面通知，表明其打算通過必要時進行反向股票拆分來彌補缺陷。如果 XTL 滿足這些要求，納斯達克將通知公司已獲得額外的 180 個日曆天。然而，如果納斯達克認為公司無法彌補缺陷，或公司其他方面不符合資格，納斯達克將發出通知，表明其證券將面臨退市。</p>
</div><p>XTL is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirements. Although XTL will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.</p>
<div class="lb-trans"><p>XTL 目前正在評估恢復合規的選項，並打算及時恢復符合納斯達克的持續上市要求。儘管 XTL 將盡一切合理努力以達到規則 5550(a)(2) 的合規要求，但不能保證公司能夠恢復對該規則的合規，或在其他納斯達克持續上市要求方面保持合規。</p>
</div><p><strong>About XTL Biopharmaceuticals Ltd.</strong></p>
<div class="lb-trans"><p><strong>關於 XTL 生物製藥有限公司</strong></p>
</div><p>XTL is an IP portfolio company. XTL holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease. The Social Proxy is a web data AI company, developing and powering a unique ethical, IP based, proxy data extraction platform for AI and BI applications at scale.</p>
<div class="lb-trans"><p>XTL 是一家知識產權組合公司。XTL 持有 The Social Proxy Ltd.（“Social Proxy”）100% 的股本，該公司是一家網絡數據公司，並已就 hCDR1 的知識產權組合進行再許可，以治療狼瘡疾病。Social Proxy 是一家網絡數據人工智能公司，開發並提供一個獨特的倫理、基於知識產權的代理數據提取平台，用於大規模的人工智能和商業智能應用。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; and (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.</p>
<div class="lb-trans"><p>本通訊包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的定義的前瞻性聲明。本通訊中包含的任何非歷史事實的陳述可能被視為前瞻性聲明。諸如 “繼續”、“將”、“可能”、“應該”、“期望”、“預計”、“計劃”、“打算”、“預期”、“相信”、“估計”、“預測”、“潛在” 等類似詞彙旨在識別此類前瞻性聲明。所有前瞻性聲明都涉及重大風險和不確定性，可能導致實際結果與前瞻性聲明中表達或暗示的結果有實質性差異，其中許多通常超出公司的控制範圍，且難以預測。這些風險和不確定性的例子包括但不限於（i）公司是否能夠收到與其 Hcdr1 知識產權相關的再許可費用，（ii）公司成功管理和整合 Social Proxy 及任何其他合資企業、業務收購、解決方案或技術的能力；（iii）意外的運營成本、交易成本及實際或或有負債；（iv）吸引和留住合格員工及關鍵人員的能力；（v）競爭加劇對公司未來業務的不利影響；（vi）公司保護其知識產權的能力；以及（vii）地方、行業及一般商業和經濟條件。可能導致實際結果與前瞻性聲明中表達或暗示的結果有實質性差異的其他因素可以在公司向證券交易委員會提交的最新 20-F 表格年度報告和 6-K 表格當前報告中找到。公司預計後續事件和發展可能導致其計劃、意圖和預期發生變化。公司不承擔任何義務，並明確聲明不打算或不承擔更新任何前瞻性聲明的責任，無論是由於新信息、未來事件還是其他原因，除非法律明確要求。前瞻性聲明僅在作出之日有效，不應被視為公司在任何後續日期的計劃和預期的代表。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p>Investor Relations, XTL Biopharmaceuticals Ltd.</p>
<div class="lb-trans"><p>投資者關係，XTL 生物製藥有限公司。</p>
</div><p>Tel: +972 3 611 6666</p>
<div class="lb-trans"><p>電話：+972 3 611 6666</p>
</div><p>Email: info@xtlbio.com</p>
<div class="lb-trans"><p>電子郵件：info@xtlbio.com</p>
</div><p>www.xtlbio.com</p>
<div class="lb-trans"><p>www.xtlbio.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXhOeU0zTXpNMU9UWTJJelV3TURBMk5qUTNPQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzAxNyM3MzM1OTY2IzUwMDA2NjQ3OA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png"/></p>

XTL 宣佈收到納斯達克關於最低出價價格不足的通知信 | XTLB 股票新聞